5-year follow-up of an RCT of 1,581 adults with untreated advanced gastroesophageal adenocarcinoma: with PD-L1 CPS ≥5, nivolumab plus chemotherapy kept its OS benefit vs chemotherapy (HR 0.71; 5-year OS 16% vs 6%). Grade 3/4 treatment-related AEs: 60% vs 45%.
RCTn = 1,581
Janjigian et al. Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649